Citadel Advisors
BOLT icon

Citadel Advisors’s Bolt Biotherapeutics BOLT Stock Holding History

Citadel Advisors’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219K Buy
56,903
+46,794
+463% +$220K ﹤0.01% 11855
2026
Q1 		$40.8K Buy
+10,109
New +$52.6K ﹤0.01% 12482
2025
Q1 		– Sell
-3,948
Closed -$42.3K – 14513
2024
Q4 		$42.3K Buy
+3,948
New +$47.7K ﹤0.01% 12560
2024
Q3 		– Sell
-118,376
Closed -$1.78M – 14273
2024
Q2 		$1.78M Sell
118,376
-2,410
-2% -$47.5K ﹤0.01% 5543
2024
Q1 		$3.38M Sell
120,786
-2,162
-2% -$50.1K ﹤0.01% 4584
2023
Q4 		$2.75M Sell
122,948
-19,734
-14% -$384K ﹤0.01% 4797
2023
Q3 		$2.97M Sell
142,682
-6,625
-4% -$162K ﹤0.01% 4502
2023
Q2 		$3.82M Buy
149,307
+7,385
+5% +$234K ﹤0.01% 4050
2023
Q1 		$3.95M Buy
141,922
+4,314
+3% +$126K ﹤0.01% 4186
2022
Q4 		$3.58M Buy
137,608
+6
+0% +$164 ﹤0.01% 4454
2022
Q3 		$4.07M Sell
137,602
-164
-0.1% -$6.79K ﹤0.01% 4220
2022
Q2 		$5.62M Buy
137,766
+158
+0.1% +$6.13K ﹤0.01% 3576
2022
Q1 		$7.54M Sell
137,608
-3,010
-2% -$203K ﹤0.01% 3429
2021
Q4 		$13.8M Sell
140,618
-3,368
-2% -$639K ﹤0.01% 2543
2021
Q3 		$36.4M Sell
143,986
-4,022
-3% -$1.14M 0.01% 1375
2021
Q2 		$44.9M Buy
148,008
+1,838
+1% +$746K 0.01% 1225
2021
Q1 		$96.2M Buy
+146,170
New +$95.1M 0.02% 600

Other funds holding BOLT

SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

Citadel Advisors's BOLT Position: Q2 2026 in Review

Citadel Advisors increased its Bolt Biotherapeutics (BOLT) stake by 463% in Q2 2026, buying an estimated $220K and bringing the position to 56,903 shares worth $219K. The position accounts for ﹤0.01% of the portfolio, ranked #11855.

Citadel Advisors first reported a position in BOLT in Q1 2021 and has held it in 17 quarters since. The position peaked at $96.2M in Q1 2021. 23 funds tracked by Wall St. Rank hold BOLT as of Q2 2026.

  • Citadel Advisors held 56,903 shares of Bolt Biotherapeutics worth $219K as of Q2 2026.
  • Citadel Advisors bought 46,794 Bolt Biotherapeutics shares in Q2 2026, an estimated $220K.
  • Bolt Biotherapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11855 holding.
  • Citadel Advisors first reported a position in Bolt Biotherapeutics in Q1 2021 and has held it in 17 quarters since.
  • Citadel Advisors's Bolt Biotherapeutics position peaked at $96.2M in Q1 2021.
  • 23 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.